Drug intelligence / Profile preview

ELI-411

Development stage: Preclinical
Lead developer: Eli Radiopharma
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

ELI-411 is a preclinical-stage theranostic radiopharmaceutical being developed by Eli Radiopharma for the treatment and imaging of solid tumors. As a theranostic agent, it is designed to be labeled with different radionuclides for either diagnostic imaging (using ⁶⁸Ga or ¹⁸F for PET) or targeted radiotherapy (using ¹⁷⁷Lu). This approach allows for the identification of patients who express the drug's target and the subsequent delivery of targeted radiation to tumor sites. The specific molecular target of ELI-411 has not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on ELI-411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELI-411.

Explore the full profile